Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1964-1966

  Smee, Donald F ^a   Reist, Elmer J ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR CYCLIC PHOSPHATE; GANCICLOVIR DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; SR 3773; SR 3775; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG RESISTANCE; ENANTIOMER; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS PLAQUE;

EID: 0029796157     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1964     Document Type: Article

References (19)

1. Bischofberger, N., M. J. M. Hitchcock, M. S. Chen, D. B. Barkhimer, K. C. Cundy, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, D. B. Mendel, D. F. Smee, and J. L. Smith. 1994. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38:2387-2391.
2. Bronson, J. J., I. Ghazzouli, M. J. M. Hitchcock, R. R. Webb II, E. R. Kern, and J. C. Martin. 1989. Synthesis and antiviral activity of nucleotide analogues bearing the (5)-(3-hydroxy-2-phosphonylmethoxy)propyl moiety attached to adenine, guanine, and cytosine, p. 88-102. In J. C. Martin (ed.), Nucleotide analogues as antiviral agents. American Chemical Society, Washington, D.C.
3. Deray, G., F. Martinez, C. Katlama, B. Levaltier, and M. Beaufils. 1989. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 9:316-321.
4. Duke, A. E., D. F. Smee, M. Chernow, R. Boehme, and T. R. Matthews. 1986. In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegaloviruses. Antiviral Res. 6:299-308.
5. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
6. Hitchcock, M. J. M., S. A. Lacy, J. R. Lindsey, and E. R. Kern. 1995. The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26:A358.
7. Ho, H.-T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41:197-202.
8. Huffman, J. H., R. W. Sidwell, A. G. Morrison, J. Coombs, and E. J. Reist. 1994. Structure-activity relationship of phosphonic acid analogs of acyclovir or ganciclovir against human cytomegalovirus in MRC-5 cells. Nucleosides Nucleotides 13:607-614.
9. Kern, E. R., J. Palmer, C. Hartline, and P. E. Vogt. 1995. Comparison of efficacy and toxicity of HPMPC and cyclic HPMPC in animal models for severe herpesvirus infections. Antiviral Res. 26:A329.
10. Lalezari, J. P., W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. Cundy, J. Hannigan, J. C. Martin, and H. S. Jaffe. 1995. (S)-1-[-3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
11. Leport, C., S. Puget, M. M. Pepin, S. Levy, C. Perronne, F. Burnvezinet, and J. L. Vilde. 1993. Cytomegalovirus resistant to foscarnet - clinicovirologic correlation in a patient with human immunodeficiency virus. J. Infect. Dis 168:1329-1330.
12. Polis, M. A., K. M. Spooner, B. F. Baird, J. F. Manischewitz, H. S. Jaffe, P. E. Fisher, J. Falloon, R. T. Davey Jr., J. A. Kovacs, R. E. Walker, S. M. Whitcup, R. B. Nussenblatt, H. C. Lane, and H. Masur. 1995. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39:882-886.
13. Reist, E. J., P. A. Sturm, R. Y. Pong, M. J. Tanga, and R. W. Sidwell. 1989. Synthesis of acyclonucleoside phosphonates for evaluation as antiviral agents, p. 17-34. In J. C. Martin (ed.), Nucleotide analogues as antiviral agents. American Chemical Society, Washington, D.C.
14. Sidwell, R. W., J. H. Huffman, D. L. Barnard, and E. J. Reist. 1989. Effect of phosphonic acid analogs of acyclovir and ganciclovir on in vitro cytomegalovirus infections. Nucleosides Nucleotides 8:833-836.
15. Smee, D. F., B. B. Barnett, R. W. Sidwell, E. J. Reist, and A. Holy. 1995. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antiviral Res. 26:1-9.
16. Smee, D. F., J. L. B. Morris, J. A. Leonhardt, J. R. Mead, A. Holy, and R. W. Sidwell. 1992. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob. Agents Chemother. 36:1837-1842.
17. Smee, D. F., S. T. Sugiyama, and E. J. Reist. 1994. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrob. Agents Chemother. 38:2165-2168.
18. Snoeck, R., T. Sakuma, E. De Clercq, I. Rosenberg, and A. Holy. 1988. (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
19. Sommadossi, J. P., and R. Carlisle. 1987. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31:452-454.